Pritumumab

Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research[1][2].

Product Specifications

CAS Number

[499212-74-7]

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pritumumab.html

Purity

97.77

Solubility

H2O

Smiles

[Pritumumab]

Molecular Weight

(144.92 kDa)

References & Citations

[1]Santosh Kesari, et al. Pritumumab binding to glioma cells induces ADCC and inhibits tumor growth. ASCO Annual Meeting I. 2017. |[2]Hugwil AV. The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human x human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy. Med Hypotheses. 2013 Sep;81 (3) :489-95.